Step by Step


ABIM MOC Activity ID

1/9/2019 - Medical Grand Rounds: Pulmonary & Critical Care Medicine - Year in Review





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Identify benefits of triple therapy as compared to LAMA monotherapy or ICS/LABA
  • Recognize the utility of immunotherapy in the treatment of advanced non-small cell lung cancer
  • Explain the role of endobronchial valve placement for lung volume reduction
  • Describe the limitations of the studies evaluating vitamin C and balanced crystalloids in critically ill patients

Suggested Additional Reading:

  1. Antonia et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med 2017; 377:1919-1929.
  2. Antonia et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379:2342-2350.
  3. Marik et al. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock. Chest 2017; 151:1229-38.
  4. Pillai et al. Comparison of the Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature. Cancer 2018; 124:271-77.
  5. Self et al. Balanced crystalloids versus saline in noncritically ill adults. N Engl J Med 2018. 378:819-828.
  6. Semler et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med 2018; 378:829-839.
  7. Sgro. Bring Yourself to Work. Journal of Graduate Medical Education 2018; 10:230-31.
  8. Soria et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:113-125.
  9. Thomson et al. Addressing Gender Inequality in Our Disciplines: Report from the Association of Pulmonary, Critical Care, and Sleep Division Chiefs. Ann Am Thorac Soc 2018; 15:1382–90.
  10. Vestbo et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomized controlled trial. Lancet 2017; 389: 1919-29.

Stephanie I Maximous, MD — Assistant Professor of Medicine
Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh
No relationships with industry relevant to the content of this educational activity have been disclosed.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.